 |
| Image created with Gemini |
You've watched the market chop sideways.
You've seen "the Magnificent Seven" get all the press, all the headlines, all the hype — and you're wondering if you've already missed the boat.
Here's the truth: the best opportunities right now are not in the stocks everyone's talking about at dinner parties.
They're in the beaten-down, forgotten, written-off names that still have rock-solid fundamentals.
I went digging through the data this April. Here are three underrated stocks that I think deserve a serious look — one Danish pharma giant, one bruised-but-not-broken athleisure brand, and one boring telecom that's quietly having its moment.
Not financial advice. I'm not your financial advisor. Do your own research before putting a single dollar anywhere.
Why April 2026 Is Actually an Interesting Time to Buy
Let me set the scene real quick.
The S&P 500 is down more than 3% so far this year. Geopolitical uncertainty, high starting valuations, and economic anxiety have been weighing on investors.
That sounds scary. And for most people, it is — because fear makes people sell.
But here's what I know: market dips are when the real wealth gets built.
When sentiment is trash and headlines are dire, that's exactly when you want to be calmly looking for quality companies trading at stupid-cheap prices.
So let's get into it.
Stock #1: Novo Nordisk (NVO) — The Ozempic Company Nobody Wants to Own Right Now
You know Ozempic. You know Wegovy.
Novo Nordisk makes both.
This company is literally one of the most dominant pharmaceutical businesses on the planet — it's been around since 1923, it's headquartered in Denmark, and it controls one of the most talked-about drug categories in the world: GLP-1 weight-loss and diabetes medications.
So why is everyone sleeping on it?
The Fear That Created the Opportunity
Novo Nordisk is anticipating a revenue decline of as much as 13% this year, and that forecast spooked investors. Shares are down a whopping 28%.
And if you zoom out even further: the stock price has decreased by 55.82% over the last 52 weeks.
Yeah, you read that right. Over half the stock's value has been wiped out.
Is the business broken? Not even close.
The Actual Numbers
Here's what the balance sheet looks like right now:
- Revenue (last 12 months): $48.59 billion
- Net profits: $16.10 billion
- Return on equity: 60.7%
- Return on invested capital: 41.1%
- Trailing P/E ratio: ~10.7x
- Dividend yield: ~3.16%
- Average analyst price target: $51.00 (vs. current price ~$37)
Novo Nordisk's P/E ratio of 10.2x compares to a peer average of 17.8x and a US Pharmaceuticals industry average of 16.5x. That's a massive discount for a company earning $16 billion a year in profit.
To put it plainly: you're buying one of the world's best pharmaceutical businesses at a P/E that wouldn't look out of place on a regional bank.
Why I'm Paying Attention
The near-term revenue dip is real. Competition in GLP-1 drugs is heating up. But this is a company actively buying back its own shares — repurchasing nearly 10 million B shares in just two months, which tells you management thinks the stock is cheap too.
The long-term obesity and diabetes market isn't going anywhere. Hundreds of millions of people globally need these treatments.
The bear case is priced in. The bull case is not.
Stock #2: Lululemon (LULU) — A Fallen Darling With a Real Recovery Path
Okay, I know what you're thinking. Lululemon? That's not underrated, that's just a mess.
Fair. Let me show you why this might be one of the better contrarian setups of 2026.
What Went Wrong
Lululemon is trading around $155 after losing more than half its value in two years, as design missteps, a CEO departure, and a $380 million tariff headwind converged into the brand's deepest operational reset in a decade.
That's a lot of bad news hitting at once. And the market priced it like the company was dying.
But here's the thing — brands with this kind of loyal customer base don't just vanish.
The Valuation Has Gotten Absurd
Lululemon is currently trading at 6.8x EV/EBITDA — a 69% discount to its own 10-year median of 22x. That multiple is approaching the all-time low of 6.63x the stock has ever seen across its entire public history.
Let that sink in. The all-time low. For a brand that still generates:
- Revenue: $11.1 billion
- Net profit: $1.58 billion
- Return on equity: 34%
- Return on invested capital: 30.6%
- Trailing P/E: ~12x (vs. historical average above 40x)
At 12.5x forward earnings, LULU trades near a decade low on its own multiple history — for a brand that compounded earnings per share at 21.7% over ten years and still holds the top U.S. women's activewear position.
The Signal I'm Watching
Smart money is putting actual dollars behind this thesis.
Two executives purchased a combined $1.5 million of LULU shares near 52-week lows in consecutive weeks, while management simultaneously guided full-price selling to improve in Q2.
When insiders are buying with their own money at lows, I pay attention.
Add to that: Lululemon's 59% gross margin and direct sales dominance continue to shield it from discount-driven erosion, with over 85% customer retention.
The China story is also building quietly. Management is targeting 20% revenue growth in mainland China and plans to open up to 20 new stores there. That's not a company in its death spiral — that's a company resetting and expanding internationally while its US business heals.
The downside looks limited. The upside, if North America recovers even partially, is significant.
ALSO READ: Top 7 Crypto Trading App With Low Fees
Stock #3: Verizon (VZ) — The "Boring" Stock That's Actually Winning
I'll be honest: I don't get excited about telecom stocks.
But sometimes the boring trade is the smart trade.
The Setup
Verizon is the only stock in this category that's actually up in 2026 — its share price has risen close to 20% year-to-date. But zoom out and it's still down 18% over the five-year window.
This is a company that for years investors just... ignored. They chased growth, AI hype, high-multiple tech — and left Verizon sitting there paying out fat dividends to whoever would have it.
Now with market uncertainty sending people into defensive plays, people are remembering it exists.
The Numbers That Matter
Verizon still trades at a forward P/E of just 10. Its wireless growth for Q4 2025 was its best in years. And its full-year guidance came in better than expected.
The dividend yield sits around 5.8% — one of the most reliable in the market.
Think about that. In an environment where people are nervous, you're collecting close to 6% annually just to hold the stock, while you wait for price appreciation.
This isn't a moonshot. It's a cash cow that the market is starting to remember exists.
Why It's Still Underrated
Despite the 20% run in 2026, Verizon is still historically cheap on a five-year basis.
The narrative hasn't fully caught up with the fundamentals yet. Most retail investors are still chasing AI names. Most finance content is still about Nvidia and cloud computing.
And that's exactly the window — before everyone agrees it's a good idea.
The Common Thread in All Three
Here's what ties these three picks together:
- Beaten down on sentiment, not fundamentals. Each one has a real business with real cash flow behind it.
- Trading at massive discounts to their own history. Not cheap vs. some random sector average — cheap vs. what the market used to pay for these exact businesses.
- Catalysts exist. A GLP-1 market that isn't shrinking, a Lululemon brand reset gaining traction internationally, and a Verizon turning a corner on wireless growth.
None of these are guaranteed. Markets can stay irrational longer than any of us expect.
But if you're looking at a 3-to-5-year horizon and you want to buy quality at a discount rather than hype at a premium — these three names are worth your research time this April.
Do your own due diligence. This is not financial advice. Past performance of any stock doesn't guarantee future results. Talk to a licensed financial advisor before making any investment decisions.
No comments:
Post a Comment